Results 71 to 80 of about 11,390 (145)

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant

Scientific Reports
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors.
Scott Thomas, Elysia Roche, Pujan Desai, Nela Pawlowska, Diana Bauer, David Gingrich, Emily Hsu, Amelia N. Deitchman, Fran Aweeka, Pamela N. Munster   +9 more
doaj   +1 more source

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. [PDF]

ESMO Open
Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J.   +11 more
europepmc   +1 more source

Mining of Respiratory System Toxicity Risk Signals for Fulvestrant Based on the Tianjin Adverse Reaction Monitoring Center and the FDA Adverse Event Reporting System Database. [PDF]

Hosp Pharm
Wang M, Han Q, Jiang Y, Liang G, Yang F.
europepmc   +1 more source

Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing. [PDF]

Cells
Huang Z, Beaufort C, Helmijr J, Zantboer B, Rozema G, Muritti C, Whien JJ, Uijterwegen A, Massimino M, Martens JWM, Jansen MPHM.   +10 more
europepmc   +1 more source

Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. [PDF]

Genes Dev
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME.   +14 more
europepmc   +1 more source

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region. [PDF]

Front Oncol
Alshehri A, Altwairgi AK, AlTourah A, Alwbari A, Chehal A, Calaud F, Al-Hashem H, Marashi H, Elsamany S, Tirmazy SH.   +9 more
europepmc   +1 more source

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025. [PDF]

Curr Oncol
Jerzak KJ, Kumar A, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Joy AA, Laing K, LeVasseur N, Lupichuk S, Sehdev S, Simmons C, Webster M, Gelmon KA, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada.   +18 more
europepmc   +1 more source

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. [PDF]

Nat Commun
Zhang P, Sun T, Wang Y, Li W, Tong Z, Phadke S, Feinstein T, Ma W, Guo P, Zhang M, Yue Y, Xu B.   +11 more
europepmc   +1 more source

Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer. [PDF]

Sci Rep
Sadetsky N, Prince P, Latimer H, Advani P, Smith-Gaziani D, Kaufman PA, Natanzon Y, Taylor A, Nguyen L, Freemantle N.   +9 more
europepmc   +1 more source

CDK4/6 inhibitor rechallenge therapy in advanced breast cancer. [PDF]

Discov Oncol
Sun Y, Zhao Y, Yu X, Qi Y, Dai X.
europepmc   +1 more source